Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.
JACC Cardiovasc Interv. 2010 Oct;3(10):995-1000
Authors: Gladding P, Panattoni L, Webster M, Cho L, Ellis S
Clopidogrel pharmacogenomics has received significant attention since a black box warning was announced by the Food and Drug Administration in March. This has left clinicians in a difficult situation where many questions remain unanswered.
SLC19A1 pharmacogenomics summary.
Pharmacogenet Genomics. 2010 Nov;20(11):708-15
Authors: Yee SW, Gong L, Badagnani I, Giacomini KM, Klein TE, Altman RB
PMID: 20811316 [PubMed - indexed for MEDLINE]
Personalized medicine: inevitable.
Rev Esp Enferm Dig. 2010 Oct;102(10):573-6
Authors: Peña AS
PMID: 21039064 [PubMed - indexed for MEDLINE]
BILLERICA, MA, (February 8, 2011) – Aushon BioSystems, Inc. , a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital (“PUCH”), Beijing, China.
Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.
Allergy Asthma Proc. 2010 May-Jun;31(3):190-202
Authors: Korenblat PE, Rosenwasser LJ
The combination of budesonide and formoterol administered in one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) is approved in the United States in two dosage strengths (budesonide/formoterol pMDI 80/4. 5 microg x 2 inhalations [160/9 microg] or 160/4.
Overview of personalized medicine in the disease genomic era.
BMB Rep. 2010 Oct;43(10):643-8
Authors: Hong KW, Oh B
Sir William Osler (1849-1919) recognized that "variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions we know as disease".
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Cancer Chemother Pharmacol. 2011 Jan;67(1):49-56
Authors: Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H, Giovanni A, Ferri-Dessens RM, Chefrour M, Favre R, Duffaud F, Seitz JF, Zanaret M, Lacarelle B, Mercier C
Fluoropyrimidine drugs are widely used in head and neck cancer (HNC).
Pharmacogenetics of toxic epidermal necrolysis.
Expert Opin Pharmacother. 2010 Sep;11(13):2153-62
Authors: Lee MT, Hung SI, Wei CY, Chen YT
Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) are two of the most severe drug-induced cutaneous reactions.
Pharmacogenomics--practice and challenges.
Aust Fam Physician. 2010 Oct;39(10):788-90
Authors: Ghosh R, Ghosh S, Chawla S
Generating revenue of over $1 billion annually to owner companies, blockbuster drugs have been a prominent feature of drug development over recent decades. However, a large number of patients have an inadequate therapeutic response to the 'one size fits all' blockbuster drugs.